Itnogen (Testosterone)

Testosterone binds to intracellular androgen receptors, forming a complex that moves into the cell nucleus and regulates gene expression. This process stimulates protein synthesis, erythropoiesis, and the development and maintenance of male secondary sexual characteristics, providing the therapeutic effects of hormone replacement.

The appropriate dose of Itnogen is determined by the prescribing clinician based on the individual’s serum testosterone levels, clinical presentation, and response to therapy. Dosage adjustments are made during follow‑up visits to achieve target hormone concentrations.

Testosterone products, including Itnogen, are not indicated for use in pregnant or breastfeeding individuals. Exposure to exogenous androgens may affect fetal development and can be transferred through breast milk, so use is contraindicated in these populations.

To order Itnogen, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Itnogen is a transdermal formulation, offering steady absorption and avoiding first‑pass metabolism, unlike oral tablets. Compared with injectable testosterone, the gel provides more convenient daily dosing and more stable serum levels, though both routes aim to normalize testosterone concentrations.

Itnogen should be stored at room temperature, below 25 °C, in its original container. Keep the product away from direct sunlight, moisture, and heat sources. Ensure the gel is sealed tightly after each use to maintain potency.

Itnogen is applied to clean, dry skin on areas such as the shoulders, upper arms, or abdomen. The prescribed amount is measured using the supplied applicator, and the site should be allowed to dry before dressing. Hands should be washed after application to prevent accidental transfer.

Serious risks include erythrocytosis, which can increase blood viscosity and raise the chance of clotting, as well as potential cardiovascular events like heart attack or stroke. Monitoring of hematocrit, blood pressure, and prostate health is essential to mitigate these risks.

Itnogen is contraindicated in men with known or suspected prostate or breast cancer, severe untreated sleep apnea, uncontrolled heart failure, or those taking anticoagulant therapy without close monitoring. Individuals with hypersensitivity to any component of the gel should also avoid its use.